collection
MENU ▼
Read by QxMD icon Read
search

Multiple Myeloma

shared collection
7 papers 0 to 25 followers
https://www.readbyqxmd.com/read/26035255/elotuzumab-therapy-for-relapsed-or-refractory-multiple-myeloma
#1
RANDOMIZED CONTROLLED TRIAL
Sagar Lonial, Meletios Dimopoulos, Antonio Palumbo, Darrell White, Sebastian Grosicki, Ivan Spicka, Adam Walter-Croneck, Philippe Moreau, Maria-Victoria Mateos, Hila Magen, Andrew Belch, Donna Reece, Meral Beksac, Andrew Spencer, Heather Oakervee, Robert Z Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Ka Lung Wu, Anil Singhal, Jesus San-Miguel, Morio Matsumoto, Jessica Katz, Eric Bleickardt, Valerie Poulart, Kenneth C Anderson, Paul Richardson
BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group)...
August 13, 2015: New England Journal of Medicine
https://www.readbyqxmd.com/read/27768093/the-role-of-maintenance-therapy-in-multiple-myeloma
#2
B Lipe, R Vukas, J Mikhael
Multiple myeloma is the second most common type of blood cancer and remains incurable despite advances in therapy. Current therapy for multiple myeloma includes a phased-approach, often consisting of initial induction therapy, consolidation and maintenance therapy. With an ever-growing landscape of treatment options, the approach to optimal therapy has become increasingly complex. Specifically, controversy surrounds the optimal use and duration of maintenance therapy. We conducted a comprehensive literature search to analyze the most current literature and to provide recommendations for maintenance therapy in multiple myeloma...
October 21, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27478200/treatment-of-relapsed-and-refractory-multiple-myeloma
#3
Pieter Sonneveld, Annemiek Broijl
No abstract text is available yet for this article.
August 2016: Haematologica
https://www.readbyqxmd.com/read/27557302/daratumumab-bortezomib-and-dexamethasone-for-multiple-myeloma
#4
RANDOMIZED CONTROLLED TRIAL
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria V Mateos, Tomer M Mark, Ming Qi, Jordan Schecter, Himal Amin, Xiang Qin, William Deraedt, Tahamtan Ahmadi, Andrew Spencer, Pieter Sonneveld
BACKGROUND: Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma. METHODS: In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib (1...
August 25, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27527838/myeloma-today-disease-definitions-and-treatment-advances
#5
Vincent Rajkumar
No abstract text is available yet for this article.
September 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27531679/phase-1-2-study-of-daratumumab-lenalidomide-and-dexamethasone-for-relapsed-multiple-myeloma
#6
Torben Plesner, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C Minnema, Ulrik Lassen, Jacob P Laubach, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A Kate Sasser, Mary E Guckert, Carla de Boer, Nushmia Z Khokhar, Howard Yeh, Pamela L Clemens, Tahamtan Ahmadi, Henk M Lokhorst, Paul G Richardson
Daratumumab, a human CD38 IgG1κ monoclonal antibody, has activity as monotherapy in multiple myeloma (MM). This phase 1/2 study investigated daratumumab plus lenalidomide/dexamethasone in refractory and relapsed/refractory MM. Part 1 (dose-escalation) evaluated 4 daratumumab doses plus lenalidomide (25 mg/day p.o. on Days 1 21 of each cycle) and dexamethasone (40 mg/week). Part 2 (dose-expansion) evaluated daratumumab at the recommended phase 2 dose (RP2D) plus lenalidomide/dexamethasone. Safety, efficacy, pharmacokinetics, immunogenicity and accelerated daratumumab infusions were studied...
August 16, 2016: Blood
https://www.readbyqxmd.com/read/27445408/a-new-era-of-immune-therapy-in-multiple-myeloma
#7
Yu-Tzu Tai, Kenneth C Anderson
No abstract text is available yet for this article.
July 21, 2016: Blood
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"